Analyst Reco. Invivyd, Inc.

Equities

IVVD

US00534A1025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
1.69 ^USD	-3.43%		-8.15%	-57.11%

May. 31	Invivyd in General Alignment With FDA on Emergency Use Authorization Pathway for Monoclonal Covid Antibodies	MT
May. 31	Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guggenheim Upgrades Invivyd to Buy From Hold, Price Target is $9	Apr. 05	MT
Invivyd Receives Upgrade to Overweight From Equalweight From Morgan Stanley, Price Target Raised to $10 From $4 Amid Pemgarda FDA Authorization	Mar. 26	MT
HC Wainwright Raises Price Target on Invivyd to $15 From $5, Keeps Buy Rating	Jan. 18	MT
Morgan Stanley Upgrades Invivyd to Equal-Weight From Underweight, Raises Price Target to $4 From $1	Dec. 19	MT
HC Wainwright Starts Invivyd at Buy With $5 Price Target	23-05-01	MT
Morgan Stanley Adjusts Price Target on Invivyd to $1 From $2, Maintains Underweight Rating	23-03-27	MT
Morgan Stanley Trims Invivyd Price Target to $2 From $3, Maintains Underweight Rating	23-01-24	MT
Stifel Adjusts Adagio Therapeutics' Price Target to $5 From $9, Reiterates Hold Rating	22-05-16	MT
Morgan Stanley Downgrades Adagio Therapeutics to Underweight Rating From Equalweight, Adjusts PT to $6 From $11	22-01-06	MT
Jefferies Downgrades Adagio Therapeutics to Hold From Buy; Price Target is $10	21-12-22	MT
Morgan Stanley Downgrades Adagio Therapeutics to Equalweight from Overweight, Adjusts Price Target to $11 from $49	21-12-15	MT
Guggenheim Downgrades Adagio Therapeutics to Neutral From Buy	21-12-15	MT
Stifel Downgrades Adagio Therapeutics to Hold From Buy, Adjusts Price Target to $9 From $50	21-12-15	MT
--Morgan Stanley Upgrades Adagio Therapeutics to Overweight From Equalweight; Price Target is $49; Shares Surge 70%	21-11-29	MT
Morgan Stanley Upgrades Adagio Therapeutics to Overweight From Equalweight; Price Target is $49	21-11-29	MT
Today on Wall Street: US tech giants return to top spot	21-08-31
ANALYST RECOMMENDATIONS : AT&T, BancorpSouth Bank, CMO Group, Magnite, Textron...	21-08-31
ADAGIO THERAPEUTICS : Morgan Stanley Starts Adagio Therapeutics at Equal-Weight With $33 Price Target	21-08-31	MT
ADAGIO THERAPEUTICS : Jefferies Starts Adagio Therapeutics at Buy With $60 Price Target	21-08-31	MT
ADAGIO THERAPEUTICS : Stifel Starts Adagio Therapeutics at Buy With $57 Price Target	21-08-31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Invivyd, Inc.

Equities

IVVD

US00534A1025

Analyst Reco.

Filters